ZA200404291B - Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor. - Google Patents
Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor. Download PDFInfo
- Publication number
- ZA200404291B ZA200404291B ZA200404291A ZA200404291A ZA200404291B ZA 200404291 B ZA200404291 B ZA 200404291B ZA 200404291 A ZA200404291 A ZA 200404291A ZA 200404291 A ZA200404291 A ZA 200404291A ZA 200404291 B ZA200404291 B ZA 200404291B
- Authority
- ZA
- South Africa
- Prior art keywords
- csf
- biologically active
- imac
- process according
- purification
- Prior art date
Links
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 title claims description 207
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 title claims description 207
- 238000000034 method Methods 0.000 title claims description 98
- 230000008569 process Effects 0.000 title claims description 83
- 238000000746 purification Methods 0.000 title claims description 60
- 238000002955 isolation Methods 0.000 title claims description 53
- 102000004169 proteins and genes Human genes 0.000 claims description 48
- 108090000623 proteins and genes Proteins 0.000 claims description 48
- 239000000243 solution Substances 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 29
- 210000003000 inclusion body Anatomy 0.000 claims description 26
- 238000011068 loading method Methods 0.000 claims description 25
- 238000004587 chromatography analysis Methods 0.000 claims description 23
- 238000002523 gelfiltration Methods 0.000 claims description 22
- 125000002091 cationic group Chemical group 0.000 claims description 21
- 238000010828 elution Methods 0.000 claims description 21
- 230000027455 binding Effects 0.000 claims description 17
- 239000012535 impurity Substances 0.000 claims description 15
- 229910021645 metal ion Inorganic materials 0.000 claims description 13
- 238000011210 chromatographic step Methods 0.000 claims description 10
- 239000003599 detergent Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 8
- 239000002609 medium Substances 0.000 claims description 6
- 238000004153 renaturation Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 5
- 238000005342 ion exchange Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 238000004925 denaturation Methods 0.000 claims description 2
- 230000036425 denaturation Effects 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 238000001641 gel filtration chromatography Methods 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims description 2
- 102100021935 C-C motif chemokine 26 Human genes 0.000 claims 14
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 claims 14
- 239000012560 cell impurity Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 description 64
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 62
- 235000018102 proteins Nutrition 0.000 description 47
- 238000000926 separation method Methods 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 229920002684 Sepharose Polymers 0.000 description 13
- 230000004071 biological effect Effects 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 239000007983 Tris buffer Substances 0.000 description 10
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000013375 chromatographic separation Methods 0.000 description 6
- 230000003297 denaturating effect Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 229960000789 guanidine hydrochloride Drugs 0.000 description 5
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 108010029961 Filgrastim Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000013522 chelant Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 4
- 238000005498 polishing Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 4
- 239000012505 Superdex™ Substances 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 229960004177 filgrastim Drugs 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 208000004235 neutropenia Diseases 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 229910052720 vanadium Inorganic materials 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010011409 Cross infection Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 108010062867 Lenograstim Proteins 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- 206010059482 Neutropenic infection Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960002618 lenograstim Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000002633 Febrile Neutropenia Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000013636 protein dimer Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 230000009962 secretion pathway Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI200100322A SI21102A (sl) | 2001-12-19 | 2001-12-19 | Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200404291B true ZA200404291B (en) | 2005-08-05 |
Family
ID=20433022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200404291A ZA200404291B (en) | 2001-12-19 | 2004-06-01 | Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor. |
Country Status (22)
Country | Link |
---|---|
US (1) | US20050159589A1 (xx) |
EP (2) | EP1458757B1 (xx) |
JP (1) | JP4454311B2 (xx) |
KR (1) | KR20040071212A (xx) |
CN (1) | CN1606568A (xx) |
AT (1) | ATE423136T1 (xx) |
AU (1) | AU2002366275B2 (xx) |
BR (1) | BR0215191A (xx) |
CA (1) | CA2469984C (xx) |
DE (1) | DE60231243D1 (xx) |
HK (1) | HK1064681A1 (xx) |
HR (1) | HRP20040572A2 (xx) |
HU (1) | HUP0402547A3 (xx) |
IL (2) | IL162448A0 (xx) |
MX (1) | MXPA04006076A (xx) |
NO (1) | NO20042967L (xx) |
NZ (1) | NZ533305A (xx) |
PL (1) | PL207775B1 (xx) |
RU (1) | RU2358980C2 (xx) |
SI (2) | SI21102A (xx) |
WO (1) | WO2003051922A1 (xx) |
ZA (1) | ZA200404291B (xx) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI21273A (sl) * | 2002-07-31 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina |
DK1439191T3 (da) * | 2004-01-19 | 2006-08-14 | Ares Trading Sa | Proces til oprensning af bakterielt udtrykte proteiner |
EP1803464A4 (en) * | 2004-09-17 | 2009-09-09 | Cellgentech Inc | TOPICAL PREPARATION FOR THE TREATMENT OF SKIN DISEASES |
US20090136444A1 (en) * | 2005-02-15 | 2009-05-28 | Apollo Life Sciences Limited | molecule and chimeric molecules thereof |
WO2006097944A2 (en) * | 2005-03-17 | 2006-09-21 | Zenotech Laboratories Limited | Process for the purification of recombinant granulocyte-colony stimulating factor |
DE102005033250A1 (de) | 2005-07-15 | 2007-01-18 | Bioceuticals Arzneimittel Ag | Verfahren zur Reinigung von G-CSF |
DE102006009437A1 (de) | 2006-03-01 | 2007-09-13 | Bioceuticals Arzneimittel Ag | G-CSF-Flüssigformulierung |
EP1878739A1 (en) * | 2006-07-14 | 2008-01-16 | LEK Pharmaceuticals D.D. | One step IMAC (MCAC) purification of proteins |
WO2008096370A2 (en) * | 2007-02-05 | 2008-08-14 | Natco Pharma Limited | An efficient and novel purification method of recombinant hg-csf |
ES2476915T3 (es) | 2007-08-27 | 2014-07-15 | Ratiopharm Gmbh | Formulación líquida de conjugado de G-CSF |
JP2009073819A (ja) * | 2007-08-29 | 2009-04-09 | Fujifilm Corp | 生理活性物質の精製方法 |
US20120093765A1 (en) * | 2009-06-16 | 2012-04-19 | Lupin Limited | Process for purification of recombinant human granulocyte colony stimulating factor |
EP2445924B2 (en) | 2009-06-25 | 2023-12-13 | Amgen Inc. | Capture purification processes for proteins expressed in a non-mammalian system |
EP3040346B1 (en) * | 2010-03-30 | 2018-02-28 | Octapharma AG | Process for the purification of granulocyte colony stimulating factor, g-csf |
CA2831787A1 (en) | 2011-03-29 | 2012-10-04 | Glaxosmithkline Llc | Buffer system for protein purification |
CN103215340A (zh) * | 2012-01-19 | 2013-07-24 | 江苏粒福特生物科技有限公司 | 一种新颖的粒细胞制备及其抗癌活性检测方法 |
HUP1200171A1 (hu) | 2012-03-19 | 2013-09-30 | Richter Gedeon Nyrt | Módszerek polipeptidek elõállítására |
HUP1200172A2 (en) * | 2012-03-19 | 2013-10-28 | Richter Gedeon Nyrt | Methods for refolding g-csf from inclusion bodies |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61227526A (ja) | 1984-07-25 | 1986-10-09 | Chugai Pharmaceut Co Ltd | 新規なコロニー刺激因子 |
EP0215126B1 (en) | 1985-02-08 | 1991-07-31 | Chugai Seiyaku Kabushiki Kaisha | Human granulocyte colony stimulating factor |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
DK203187A (da) | 1986-04-22 | 1987-10-23 | Immunex Corp | Human g-csf proteinekspression |
US5055555A (en) | 1989-01-05 | 1991-10-08 | Helmut Sassenfeld | Purification of G-CSF |
US5169936A (en) | 1989-04-14 | 1992-12-08 | Biogen, Inc. | Protein purification on immobilized metal affinity resins effected by elution using a weak ligand |
US5932102A (en) | 1998-01-12 | 1999-08-03 | Schering Corporation | Immobilized metal, affinity chromatography |
FR2796071B1 (fr) * | 1999-07-08 | 2001-09-07 | Hoechst Marion Roussel Inc | Procede de purification de facteur de stimulation de colonies de granulocytes |
-
2001
- 2001-12-19 SI SI200100322A patent/SI21102A/sl not_active IP Right Cessation
-
2002
- 2002-12-05 CN CNA028254651A patent/CN1606568A/zh active Pending
- 2002-12-05 HU HU0402547A patent/HUP0402547A3/hu unknown
- 2002-12-05 US US10/499,315 patent/US20050159589A1/en not_active Abandoned
- 2002-12-05 NZ NZ533305A patent/NZ533305A/en unknown
- 2002-12-05 BR BR0215191-0A patent/BR0215191A/pt not_active Application Discontinuation
- 2002-12-05 DE DE60231243T patent/DE60231243D1/de not_active Expired - Lifetime
- 2002-12-05 AU AU2002366275A patent/AU2002366275B2/en not_active Ceased
- 2002-12-05 MX MXPA04006076A patent/MXPA04006076A/es active IP Right Grant
- 2002-12-05 PL PL369669A patent/PL207775B1/pl unknown
- 2002-12-05 SI SI200230822T patent/SI1458757T1/sl unknown
- 2002-12-05 KR KR10-2004-7009409A patent/KR20040071212A/ko not_active Application Discontinuation
- 2002-12-05 EP EP02804876A patent/EP1458757B1/en not_active Expired - Lifetime
- 2002-12-05 AT AT02804876T patent/ATE423136T1/de active
- 2002-12-05 EP EP09152902A patent/EP2053061A1/en not_active Withdrawn
- 2002-12-05 IL IL16244802A patent/IL162448A0/xx unknown
- 2002-12-05 JP JP2003552802A patent/JP4454311B2/ja not_active Expired - Fee Related
- 2002-12-05 CA CA2469984A patent/CA2469984C/en not_active Expired - Fee Related
- 2002-12-05 WO PCT/EP2002/013810 patent/WO2003051922A1/en active IP Right Grant
- 2002-12-05 RU RU2004121982/13A patent/RU2358980C2/ru not_active IP Right Cessation
-
2004
- 2004-06-01 ZA ZA200404291A patent/ZA200404291B/en unknown
- 2004-06-10 IL IL162448A patent/IL162448A/en not_active IP Right Cessation
- 2004-06-18 HR HR20040572A patent/HRP20040572A2/xx not_active Application Discontinuation
- 2004-07-14 NO NO20042967A patent/NO20042967L/no not_active Application Discontinuation
- 2004-09-23 HK HK04107314.0A patent/HK1064681A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HUP0402547A2 (hu) | 2005-03-29 |
EP2053061A1 (en) | 2009-04-29 |
SI21102A (sl) | 2003-06-30 |
CN1606568A (zh) | 2005-04-13 |
HUP0402547A3 (en) | 2010-01-28 |
RU2004121982A (ru) | 2005-04-20 |
HRP20040572A2 (en) | 2005-06-30 |
NO20042967L (no) | 2004-09-07 |
BR0215191A (pt) | 2004-11-16 |
JP4454311B2 (ja) | 2010-04-21 |
US20050159589A1 (en) | 2005-07-21 |
CA2469984C (en) | 2014-05-20 |
EP1458757A1 (en) | 2004-09-22 |
CA2469984A1 (en) | 2003-06-26 |
AU2002366275A1 (en) | 2003-06-30 |
KR20040071212A (ko) | 2004-08-11 |
MXPA04006076A (es) | 2005-02-24 |
IL162448A0 (en) | 2005-11-20 |
EP1458757B1 (en) | 2009-02-18 |
PL207775B1 (pl) | 2011-01-31 |
SI1458757T1 (sl) | 2009-10-31 |
AU2002366275B2 (en) | 2009-04-02 |
RU2358980C2 (ru) | 2009-06-20 |
WO2003051922A1 (en) | 2003-06-26 |
NZ533305A (en) | 2005-11-25 |
PL369669A1 (en) | 2005-05-02 |
JP2005525304A (ja) | 2005-08-25 |
ATE423136T1 (de) | 2009-03-15 |
DE60231243D1 (de) | 2009-04-02 |
IL162448A (en) | 2010-12-30 |
HK1064681A1 (en) | 2005-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002366275B2 (en) | Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor | |
Yoshimura et al. | Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. | |
EP0401384B1 (en) | Chemically modified granulocyte colony stimulating factor | |
EP1037657B1 (en) | Alpha-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same | |
EP0228452B1 (en) | Protein purification | |
KR910700336A (ko) | 조작형 플라스미노겐 활성화제의 유도체 | |
EP1878739A1 (en) | One step IMAC (MCAC) purification of proteins | |
US5196323A (en) | Process for preparing and purifying alpha-interferon | |
EA035448B1 (ru) | СПОСОБ ОЧИСТКИ рчГ-КСФ | |
JP2566919B2 (ja) | α−インタ−フエロンの製造方法 | |
RU2278870C2 (ru) | Способ получения, выделения, очистки и стабилизации рекомбинантного гранулоцитарного колониестимулирующего фактора человека, пригодного для медицинского применения, и иммунобиологическое средство на его основе | |
US20080293924A1 (en) | Process For the Isolation and/or Purification of Proteins | |
JP3200850B2 (ja) | ヒトbcdfの精製法 | |
KR100531670B1 (ko) | 인체 인터페론 알파의 제조방법 | |
JPH022390A (ja) | 新規なヒト顆粒球マクロファージコロニー刺激因子 | |
JPH11335395A (ja) | 精製ヒトアクチビン及びその製造方法 | |
EP0446850A2 (en) | Process for purifying recombinant human beta-interferon | |
Rosenberg | 4894440 Method of isolating megakaryocyte stimulatory factor | |
JPH07103041B2 (ja) | 悪性腫瘍治療補助剤 |